PF-6260933CAS号： 1811510-56-1分子式： C16H13ClN4分子量： 296.76描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively. |
| 纯度 |
98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
PF 06260933；PF06260933；PF6260933；PF 6260933；PF-6260933
|
| 外观 |
powder
|
| 可溶性/溶解性 |
DMSO : 30 mg/mL (101.10 mM; Need ultrasonic and warming)
|
| 生物活性 | |
| 靶点 |
MAP4K4 for Cell,MAP4K4 for Kinase,MAP4K4
|
| In vitro(体外研究) |
PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability in vitro, similar to MAP4K4 knockdown.
|
| In vivo(体内研究) |
In the mice model, PF-06260933 treatment does not alter plasma lipid content, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed.
|
分子结构图
